Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

• Sponsor: M.D. Anderson Cancer Center (Other)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT03132467
• Collaborator: National Cancer Institute (NCI) (NIH)
• Enrollment: 16
• Location: 1
• Arm: 1
• Anticipated Duration (Months): 84.6
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

This early phase I trial studies the side effects of durvalumab and tremelimumab before surgery in treating patients with hormone receptor positive, HER2 negative stage II-III breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Condition or Disease	Intervention/Treatment	Phase
Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8	Biological: Durvalumab; Biological: Tremelimumab	Early Phase 1

Detailed Description

PRIMARY OBJECTIVES:

1. To evaluate the feasibility of enrolling patients with hormone receptor positive (HR+)/human epidermal growth factor receptor negative (HER2-) breast cancer onto a trial evaluating investigational agents prior to initiating standard neoadjuvant chemotherapy.

2. To evaluate the safety and tolerability of tremelimumab plus durvalumab in patients with HR+/HER2- breast cancer.

SECONDARY OBJECTIVES:

1. To assess immunologic/molecular responses to tremelimumab and durvalumab in patients with HR+/HER2- breast cancer who receive the combination therapy.

EXPLORATORY OBJECTIVES:

1. To evaluate the pathologic response in patients with HR+/HER2- breast cancer receiving tremelimumab plus durvalumab prior to initiating standard neoadjuvant chemotherapy.

OUTLINE:

Patients receive tremelimumab intravenously (IV) over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.

After completion of study treatment, patients are followed up until the time of surgery.

Study Design

• Study Type: Interventional
• Actual Enrollment: 16 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
• Actual Study Start Date: Jun 13, 2017
• Actual Primary Completion Date: Jan 31, 2019
• Anticipated Study Completion Date: Jun 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (tremelimumab, durvalumab) Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.	Biological: Durvalumab; Given IV; Other Names: Imfinzi Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer MEDI-4736 MEDI4736 ; Biological: Tremelimumab; Given IV; Other Names: Anti-CTLA4 Human Monoclonal Antibody CP-675,206 CP-675 CP-675,206 CP-675206 Ticilimumab

Outcome Measures

Primary Outcome Measures

1. Feasibility of Enrolling 15 Patients Within 2 Years [Up to 2 years]

   Feasibility established if all 15 patients enroll within 12 months of starting the study. The start date for measuring feasibility will be the date the first patient is screened.

2. Safety and Tolerability of Tremelimumab Plus Durvalumab in Participants With HR+/HER2 Neg Breast Cancer. [2 months]

   To evaluate the safety and tolerability of tremelimumab plus durvalumab in patients with HR+/HER2 neg breast cancer. Adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v4.03.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Written informed consent and any locally-required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA]) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Hormone receptor positive (defined as estrogen receptor [ER] and/or progesterone receptor [PR] positive), HER2 negative breast cancer that is clinically staged II-III with no known metastatic disease. ER and/or PR defined as positive if expression > 10% by immunohistochemistry (IHC). HER2 negative or non-amplified as determined by the current American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) criteria which are as follows: HER2 testing by immunohistochemistry (IHC) as 0 or 1+. If HER2 is 2+, ISH (in situ hybridization) must be performed. HER2 is positive if: IHC 3+ based on circumferential membrane staining that is complete, intense ISH positive based on: 1) Single-probe average HER2 copy number >= 6.0 signals/cell, 2) Dual-probe HER2/CEP17 ratio >= 2.0; c,e with an average HER2 copy number >= 4.0 signals/cell, 3) Dual-probe HER2/CEP17 ratio >= 2.0; c,e with an average HER2 copy number < 4.0 signals/cell, 4) Dual-probe HER2/CEP17 ratio < 2.0; c,e with an average HER2 copy number >= 6.0 signals/cell

• Chemotherapy is planned for the patient in the neoadjuvant setting

• Hemoglobin >= 9.0 g/dL

• Absolute neutrophil count (ANC) >=1.5 x 10^{9/L (>= 1500 per mm}3)

• Platelet count >= 100 x 10^{9/L (>= 100,000 per mm}3)

• Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only upon treating physician, principal investigators (PI) or co-PIs approval

• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =< 5 x ULN

• Creatinine clearance (CL) > 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance

• Female subjects must either be of non-reproductive potential (i.e., post-menopausal by history: >= 60 years old and no menses for >= 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative urine pregnancy test upon study entry

• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

Exclusion Criteria:

• Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)

• Participation in another clinical study with an investigational product during the last 1 month prior to initiation of therapy

• Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab

• History of another primary malignancy except for:

• Malignancy treated with curative intent and with no known active disease >= 5 years before the first dose of study drug and of low potential risk for recurrence

• Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease

• Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ

• Has received therapy for this current diagnosis of breast cancer including endocrine therapy or chemotherapy

• A single QT interval corrected for heart rate (QTc) >= 470 ms. If an electrocardiogram (ECG) is interpreted to be a prolonged QT interval, 2 additional ECGs will be obtained and the PI will then evaluate all three ECGs and determine whether the patient should be excluded. Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's correction

• Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid

• Active or prior documented autoimmune disease within the past 2 years

• NOTE: Subjects with vitiligo, Graves disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded

• Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)

• History of primary immunodeficiency

• History of allogeneic organ transplant

• History of hypersensitivity to durvalumab or tremelimumab or any excipient

• History of hypersensitivity to the combination or comparator agent (if applicable)

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent

• Known history of previous clinical diagnosis of tuberculosis

• History of leptomeningeal carcinomatosis

• Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab

• Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control

• Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results

• Subjects with uncontrolled seizures

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	M D Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• M.D. Anderson Cancer Center
• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Jennifer K Litton, M.D. Anderson Cancer Center

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Oct 5, 2018

More Information

Additional Information:

• University of Texas MD Anderson Cancer Center Website

Publications

None provided.

• Responsible Party: M.D. Anderson Cancer Center
• ClinicalTrials.gov Identifier: NCT03132467
• Other Study ID Numbers: 2016-0902; NCI-2018-01189; 2016-0902
• First Posted: Apr 27, 2017
• Last Update Posted: Feb 17, 2022
• Last Verified: Jan 1, 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Breast Neoplasms; Durvalumab; Ipilimumab; Tremelimumab; Immunoglobulins; Antibodies, Monoclonal; Immunoglobulin G

Study Results

Participant Flow

Recruitment Details	This was a feasibility trial of combined checkpoint blockade in patients with HR+/HER2 neg primary breast cancer to determine whether the strategy of combined checkpoint blockade therapy prior to chemotherapy could be an effective frontline therapy. Patients were eligible if they had hormone receptor positive, HER2 negative breast cancer and had neoadjuvant chemotherapy planned.
Pre-assignment Detail	16 participants enrolled, 8 participants were inevaluable.

Arm/Group Title	Treatment (Tremelimumab, Durvalumab)
Arm/Group Description	Patients were treated with durvalumab at a dose of 1500 mg and tremelimumab at a dose of 75 mg, both administered IV, for 2 cycles on days 1 and 28 Patients then received standard neoadjuvant chemotherapy prior to breast surgery Pre- and post-treatment tumor biopsies and blood samples were available for 5 out of 8 patients and were analyzed by CyTOF, IHC, and NanoString"
Period Title: Overall Study
STARTED	8
COMPLETED	4
NOT COMPLETED	4

Baseline Characteristics

Arm/Group Title	Treatment (Tremelimumab, Durvalumab)
Arm/Group Description	Patients were treated with durvalumab at a dose of 1500 mg and tremelimumab at a dose of 75 mg, both administered IV, for 2 cycles on days 1 and 28 Patients then received standard neoadjuvant chemotherapy prior to breast surgery Pre- and post-treatment tumor biopsies and blood samples were available for 5 out of 8 patients and were analyzed by CyTOF, IHC, and NanoString"
Overall Participants	8
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	55
Sex: Female, Male (Count of Participants)
Female	8 100%
Male	0 0%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%
Not Hispanic or Latino	8 100%
Unknown or Not Reported	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	1 12.5%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	0 0%
White	7 87.5%
More than one race	0 0%
Unknown or Not Reported	0 0%
Region of Enrollment (participants) [Number]
United States	8 100%

Outcome Measures

1. Primary Outcome

Title	Feasibility of Enrolling 15 Patients Within 2 Years
Description	Feasibility established if all 15 patients enroll within 12 months of starting the study. The start date for measuring feasibility will be the date the first patient is screened.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

The trials primary endpoint of 15 participants enrollment feasibility within 2 years was NOT met due to early termination of the study.

Arm/Group Title	Treatment (Tremelimumab, Durvalumab)
Arm/Group Description	Patients were treated with durvalumab at a dose of 1500 mg and tremelimumab at a dose of 75 mg, both administered IV, for 2 cycles on days 1 and 28 Patients then received standard neoadjuvant chemotherapy prior to breast surgery Pre- and post-treatment tumor biopsies and blood samples were available for 5 out of 8 patients and were analyzed by CyTOF, IHC, and NanoString"
Measure Participants	8
Count of Participants [Participants]	8 100%

2. Primary Outcome

Title	Safety and Tolerability of Tremelimumab Plus Durvalumab in Participants With HR+/HER2 Neg Breast Cancer.
Description	To evaluate the safety and tolerability of tremelimumab plus durvalumab in patients with HR+/HER2 neg breast cancer. Adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v4.03.
Time Frame	2 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Treatment (Tremelimumab, Durvalumab)
Arm/Group Description	Participants with stage II or III HR+/HER2 negative breast cancer who were to receive neoadjuvant chemotherapy
Measure Participants	8
Serious Adverse Events	3
Adverse Events	8

Adverse Events

Time Frame	2 months
Arm/Group Title	Treatment (Tremelimumab, Durvalumab)
Arm/Group Description	Patients were treated with durvalumab at a dose of 1500 mg and tremelimumab at a dose of 75 mg, both administered IV, for 2 cycles on days 1 and 28 Patients then received standard neoadjuvant chemotherapy prior to breast surgery Pre- and post-treatment tumor biopsies and blood samples were available for 5 out of 8 patients and were analyzed by CyTOF, IHC, and NanoString"
All Cause Mortality
	Treatment (Tremelimumab, Durvalumab)
	Affected / at Risk (%)	# Events
Total	0/8 (0%)
Serious Adverse Events
	Treatment (Tremelimumab, Durvalumab)
	Affected / at Risk (%)	# Events
Total	3/8 (37.5%)
Endocrine disorders
Adrenal insufficiency	1/8 (12.5%)	1
Hyperthyroidism	1/8 (12.5%)	1
Gastrointestinal disorders
Colitis	1/8 (12.5%)	1
Other (Not Including Serious) Adverse Events
	Treatment (Tremelimumab, Durvalumab)
	Affected / at Risk (%)	# Events
Total	8/8 (100%)
Endocrine disorders
Hot flashes	1/8 (12.5%)	1
Eye disorders
Conjunctivits	1/8 (12.5%)	1
Gastrointestinal disorders
Constipation	1/8 (12.5%)	1
Diarrhea	1/8 (12.5%)	1
Dysgeusia	1/8 (12.5%)	1
Mucositis	2/8 (25%)	2
Skin and subcutaneous tissue disorders
Pruritis	1/8 (12.5%)	1
Rash	2/8 (25%)	2

Limitations/Caveats

The trial was stopped early after 2 of 8 patients experienced G3 immunerelated adverse events.

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.